World's Best Scientists 2026 revealed!
James E. Herndon

James E. Herndon

D-Index & Metrics

Medicine

D-Index
132
Citations
63935
World Ranking
2318
National Ranking
1310

James E. Herndon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James E. Herndon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 602 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James E. Herndon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James E. Herndon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 132 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James E. Herndon is affiliated with Duke University in the United States. Their research primarily focuses on Medicine, with significant contributions across Oncology, Pulmonary and Respiratory Medicine, Genetics, Radiology, Nuclear Medicine and Imaging, and Immunology.

The main research topics covered by Herndon include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Immunotherapy and Immune Responses
  • Cancer Research and Treatments
  • CAR-T cell therapy research
  • Cancer survivorship and care

Herndon's work has been published extensively in several prominent venues, with the most frequent including:

  • Neuro-Oncology
  • Neuro-Oncology Advances
  • Journal of Clinical Oncology
  • UNC Libraries
  • Neuro-Oncology Practice

Among recent notable publications are:

  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, 2021, Nature Communications
  • Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma, 2020, Clinical Cancer Research
  • Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer, 2020, Circulation
  • Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial, 2021, Journal of Cachexia Sarcopenia and Muscle
  • Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial, 2023, The Lancet Child & Adolescent Health

Frequent collaborators include Annick Desjardins, Katherine B. Peters, David M. Ashley, Margaret Johnson, and Henry S. Friedman. The number of joint publications with these coauthors ranges from 37 to 44, reflecting ongoing research partnerships.

Best Publications

  • IDH1 and IDH2 Mutations in Gliomas

    Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial

    Robert O. Dillman;James Herndon;Stephen L. Seagren;Walter L. Eaton

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

    Gary M. Strauss;James E. Herndon;Michael A. Maddaus;David W. Johnstone

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial

    Mark S. Allen;Gail E. Darling;Taine T.V. Pechet;John D. Mitchell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • Video-Assisted Thoracic Surgery Lobectomy: Report of CALGB 39802—A Prospective, Multi-Institution Feasibility Study

    Scott J. Swanson;James E. Herndon;Thomas A. D'Amico;Todd L. Demmy

  • Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

    Carolyn M Dresler;Jemi Olak;James E Herndon;William G Richards

  • Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial

    Lee Gravatt Wilke;Linda M. McCall;Katherine E. Posther;Pat W. Whitworth

  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

    Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie

  • Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

    James E. Herndon;Mark R. Green;A. Phillippe Chahinian;Joseph M. Corson

  • Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

    Rogerio C. Lilenbaum;James E. Herndon;Marcy A. List;Chris Desch

  • Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

    Everett E. Vokes;James E. Herndon;Michael J. Kelley;M. Giulia Cicchetti

  • Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

    Alice B. Kornblith;James E. Herndon;Lewis R. Silverman;Erin P. Demakos

  • Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial

    Amy P Abernethy;Amy P Abernethy;Amy P Abernethy;Christine F McDonald;Peter A Frith;Katherine Clark

  • Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

    G. M. Strauss;J. Herndon;M. A. Maddaus;D. W. Johnstone

  • TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL

    Hai Yan;P.J. Killela;Z.J. Reitman;Y. Jiao

Frequent Co-Authors

Henry S. Friedman
Henry S. Friedman Duke University
John H. Sampson
John H. Sampson Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Darell D. Bigner
Darell D. Bigner Duke University
David A. Reardon
David A. Reardon Harvard University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Roger E. McLendon
Roger E. McLendon Duke University
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Gary E. Archer
Gary E. Archer Duke University
Amy P. Abernethy
Amy P. Abernethy Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering alternative routes into the healthcare sector or looking to advance their careers, online programs offer flexible and accessible options. With rising demand for nurses and healthcare professionals, the range of online degree pathways has expanded significantly.

Affordability is a key consideration for many students. Prospective doctoral candidates might explore the cheapest phd nursing programs to reduce financial burden while reaching the highest academic levels in nursing.

Registered Nurses (RNs) seeking career advancement can benefit from rn to bsn online pathways, enabling them to earn a bachelor’s degree with flexible schedules and often lower costs.

For individuals who already hold a non-nursing bachelor’s degree but want to enter the field, options like msn direct entry programs online allow faster access to advanced nursing roles without starting from scratch.

Additionally, those looking for accessible entry points into nursing can find online bsn programs for non nurses, which are designed to remove admission barriers and accelerate entry into the profession.

Best Scientists Citing James E. Herndon

Trending Scientists

Recently Published Articles